文献速递临床试验与 GCP

脑膜中动脉栓塞预防慢性硬膜下血肿术后复发:EMPROTECT随机临床试验

Meningeal Embolization for Preventing Chronic Subdural Hematoma Recurrence After Surgery: The EMPROTECT Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-01

这项多中心、开放标签、盲法终点评估的随机临床试验纳入342例因慢性硬膜下血肿复发或首次发病高复发风险而接受手术的患者,1:1随机接受术后7天内脑膜中动脉栓塞联合标准医疗或单纯标准医疗。6个月时复发率在干预组为14.8%、对照组为21.0%,差异未达统计学显著(校正绝对差-6%,95%CI -14%至2%;P=0.13),次要终点亦无显著差异。

要点

  • 术后7天内行脑膜中动脉栓塞未显著降低6个月慢性硬膜下血肿复发率(14.8% vs 21.0%,P=0.13)。
  • 复发再手术率在干预组为4.3%、对照组为8.3%,差异无统计学显著(P=0.14)。
  • 栓塞操作相关轻微并发症3例(1.8%)、严重并发症1例(0.6%),均发生于干预组171例中。

核心结论

  • 在因慢性硬膜下血肿复发或首次发病高复发风险而接受手术的患者中,脑膜中动脉栓塞未较单纯标准医疗显著降低6个月复发率。
  • 作者认为效应估计幅度与其他近期试验一致,包括部分显示非黏附性液体栓塞剂行脑膜中动脉栓塞有益的试验,这些发现综合起来可能为未来研究和该治疗方法的潜在应用提供信息。

研究设计与样本

  • 多中心、开放标签、盲法终点评估的随机临床试验,2020年7月至2023年3月在12家法国神经外科或综合神经外科与介入神经放射中心招募患者,末次随访于2023年11月2日。
  • 纳入因慢性硬膜下血肿复发或首次发病高复发风险而接受手术的患者,1:1随机分为术后7天内行微粒脑膜中动脉栓塞组(171例)或单纯标准医疗组(171例)。
  • 主要终点为6个月时经独立盲法裁定委员会评估的慢性硬膜下血肿复发率,共5个次要终点,包括6个月随访期间同侧慢性硬膜下血肿复发再手术率和栓塞操作相关并发症率。
  • 342例随机患者中位(IQR)年龄77(68-83)岁,274例(80.1%)为男性,308例(90.1%)完成试验。

主要发现

  • 主要终点在干预组162例中观察到24例(14.8%),对照组157例中观察到33例(21.0%)(插补后比值比0.64,95%CI 0.36-1.14;校正绝对差-6%,95%CI -14%至2%;P=0.13)。
  • 两组在任何次要终点上均无显著差异。
  • 同侧慢性硬膜下血肿复发再手术在干预组162例中为7例(4.3%),对照组157例中为13例(8.3%)(P=0.14)。
  • 栓塞操作相关轻微并发症在干预组171例中为3例(1.8%),严重并发症在干预组171例中为1例(0.6%)。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Middle meningeal artery (MMA) embolization has been proposed as a potential treatment for chronic subdural hematoma (CSDH). OBJECTIVE: To assess the efficacy of MMA embolization in reducing the risk of CSDH recurrence at 6 months compared with standard care in patients who underwent an operation and were at high risk of CSDH recurrence. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, open-label, randomized clinical trial with blinded end point assessment. Patients who underwent an operation for CSDH recurrence or a first CSDH episode at high risk of recurrence were recruited from July 2020 to March 2023 in 12 French neurosurgical or comprehensive neurosurgical and interventional neuroradiology centers. Last follow-up took place on November 2, 2023. INTERVENTION: Participants were randomized 1:1 to undergo MMA embolization with microparticles within 7 days of surgery (171 patients, intervention group) or standard medical care alone (171 patients, control group). MAIN OUTCOMES AND MEASURES: The primary end point was the rate of CSDH recurrence at 6 months assessed by an independent, blinded adjudication committee. There were 5 secondary end points, including rates of repeat surgery for homolateral CSDH recurrence during the 6-month follow-up period and embolization procedure-related complications. RESULTS: Among 342 randomized patients (median [IQR] age, 77 [68-83] years; 274 [80.1%] male), 308 (90.1%) completed the trial. The primary end point was observed in 24 of 162 (14.8%) and 33 of 157 (21.0%) patients in the intervention and control groups, respectively (after imputation: odds ratio, 0.64 [95% CI, 0.36-1.14]; adjusted absolute difference, -6% [95% CI, -14% to 2%]; P = .13). The groups did not significantly differ in any of the secondary end points. Repeat surgery was performed in 7 of 162 (4.3%) and 13 of 157 (8.3%) patients in the intervention and control groups (P = .14), respectively. Minor and major embolization procedure-related complications occurred in 3 of 171 (1.8%) and 1 of 171 (0.6%) patients, respectively. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, among patients who underwent an operation for CSDH recurrence or a first CSDH episode at high risk of recurrence, MMA embolization did not lead to a significantly lower rate of recurrence at 6 months compared with standard medical care alone. However, the magnitude of the effect estimate is consistent with other recent trials, including some that demonstrated the benefit of MMA embolization with nonadhesive liquid embolic agents, and these findings considered together may inform future studies and potential use of this therapeutic approach for CSDH management. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04372147.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Shotar E, Mathon B, Salle H, et al. Meningeal Embolization for Preventing Chronic Subdural Hematoma Recurrence After Surgery: The EMPROTECT Randomized Clinical Trial. JAMA. 2025. PMID: 40471557. doi:10.1001/jama.2025.7583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。